Afabicin

Published
Topics: New Medicines

dm+d

Unassigned

New Medicines

Skin and skin structure infections

Information

New molecular entity
Debiopharm
Debiopharm

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Some other antibacterials (05.01.07)
A prodrug of the small-molecule, enoyl ACP reductase (FabI) inhibitor, Debio 1452. Debio 1450 is the first in a new class of antibacterials that inhibit bacterial fatty acid biosynthesis.
In England in 2018/19, there were ~241,000 finished consultant episodes of skin infections including cellulitis, local infections of skin tissues and cutaneous abscess. Up to 10% receive targeted antimicrobial therapy based on antibiotic resistance rates (~40 per 100,000 people), rather than empirical therapy. [10]
Skin and skin structure infections
acute, due to staphylococci
Intravenous